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SUMMARY
In this thesis, applications and limitations of pharmacoeconomics in the
evaluation of prevention strategies are discussed. In part 1, some of the current
methodological issues are discussed. Part 2 shows some current applications of
pharmacoeconomics in the field of vaccine preventable diseases, while part 3
evaluates some of the aspects of HIV prevention.
Chapter 2 elaborates on the development of models to assess the future impact
of vaccination strategies. It is noted that often not only progression of disease
and associated costs are important, but also the transmission of the causing
agent in the target population should be considered. A distinction can be made
between models that incorporate the external effects of reducing transmission
of disease, (dynamic transmission models) and models that do not incorporate
this externality (static models). Static models are by far the most widely used
in economic evaluations. However, a dynamic transmission model should be
considered when the force of infection is likely to be altered due to the
intervention. This occurs when the intervention affects the transmission of the
causing agent. Such models have some downsides, in being more complex and
the necessity of detailed insights in the transmission dynamics of the disease.
Especially the latter will not always be available, forcing the analyst to use
simpler models instead. Nevertheless, both the analyst and policy makers
should be aware of the limitations of those models, such as the fact that a
dynamic model can account for the effects of shifts in age-specific incidence,
the occurrence of herd immunity and the consequences of less than optimal
vaccination rates.
267
The use of cost-effectiveness analysis for rational decision-making requires an
implicit valuation of what is considered cost-effective. In the literature, values
for such a single threshold value for the willingness to pay per QALY have
been proposed. Large differences exist in the cost-effectiveness ratio of
implemented interventions in the field of blood safety when compared to
vaccination. This seems to contradict the existence of a single threshold as the
decision rule in cost-effectiveness analysis. In chapter 3, factors inÍluencing the
cost-effectiveness threshold are identified and the implications of using
thresholds for cost-effectiveness in the decision-making process are discussed.
The use of a single threshold value for cost-effectiveness analysis ignores the
reality of a fixed budget, where additional funding must come from cuts in
other programs. This may thus cause expenditures for health care to rise. Also,
in this chapter we argue that the willingness to pay per QALY is depended on
the context and should not be generalized. In conclusion, the use of a
threshold value for cost-effectiveness as the decision rule could have serious
implications and is based on political considerations and not necessarily
supported by science.
One of the most influential factors in the evaluation of preventive
interventions with future health benefits is the valuing of future health
benefits. One of the findings in chapter 4 is the fact that these decisions affect
the results of prevention studies to the greatest extent, and completely inverse
the study results in some instances. In this chapter, an overview is presented of
the main current views on the valuation of future health gains. Two areas of
controversy are identified, namely the use of similar or differential discount
rates for health and money; and the choice of the underlying discounting
model. A number of convincing arguments are found that contradict the
current practice of discounting health and money at the social rate of time
preference.
268
In chapter 5, an altemative framework for the measurement of health gains of
preventive interventions is developed. It is argued that denominators such as
life years gained or QALYs are only indirect and partial measures of the effects
of a preventive intervention. The actual effect of the intervention could be
measured as a reduction of the risk of exposure in a given period of time. This
risk reduction will not always coincide with the timing of the impact on
(quality-adjusted) life years gained (i.e. at risk exposure/ e.g. preventing
chronic disease with an asymptomatic stage). In chapter 5, we thus show that
truly acknowledging the origin of health benefits could have implications for
the discounting procedure. As an altemative, a discounting procedure is
presented that adequately focuses on the reduction of risk. This chapter also
discusses the associated potential implications for public health policy and
discuss how the effects of the intervention can be additionally corrected for
societal preferences.
In the second part of this thesis, applications of pharmacoeconomic evaluation
are presented. In chapter 6, the impact of influenza vaccination of all elderly in
The Netherlands is projected from the healthcare perspective. The modelling
framework for the economic evaluation linked epidemiological aspects oÍ
influenza (e.g. incidence, mortality, years of life lost) to vaccination coverag€
and healthcare resource use. The cost-effectiveness ratio was estimated al
€1820 per life year gained. Subgroup analysis demonstrated that the
programme had a more favourable cost-effectiveness among the chronically il1
elderly population (cost-saving) than among the rest of the elderly populatior
(€6900 per life-year gained). Influenza vaccination has a favourable cost'
effectiveness ratio compared to other implemented Dutch Programmes in tht
prevention of infectious diseases.
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In chapter 7, the future impact of vaccinating infants with meningococcal B
vaccine is estimated by applying decision-analysis. In this simulation model,
vaccination would prevent 1-9 deaths and 8 cases with severe long-term
sequelae per year, rendering 526 QALYs per year. The program costs of
meningococcal vaccination are estimated at €8,267,300, resulting in a cost-
effectiveness ratio of €15,720 per QALY. At this baseline value, meningococcal
B vaccination of infants in The Netherlands might be a potential cost-effective
intervention.
Streptococcus pneumoniae is one of the main causes of meningitis, bacteremia,
pneumonia and otitis media. In chapter 8, epidemiological impact and cost-
effectiveness analysis of vaccinating infants in the Netherlands with a 7-valent
conjugated pneumococcal vaccine is estimated using decision analysis. A
model is used to simulate vaccination of all. Introduction of the vaccine would
prevent 48 cases of meningitis and 88 cases oÍ pneumococcal bacteremia per
year. Additionally, 34L1 cases of pneumococcal pneumonia and 42,695 cases of
otitis media would be prevented. This translates into 382 quality adjusted life
years gained or 329 discounted life years gained, or. With a vaccine price of
€40 per dose, base case cost-effectiveness i  €7L,250 per QALY. The model is
sensitive to changes in incidence of disease and vaccine price. The introduction
of this vaccine for infants will lead to large reductions in morbidity and
mortality. However, compared to other interventions in the Netherlands, the
cost-effectiveness ratio at the baseline level is relativelv unfavourable.
Pharmacoeconomic evaluations can be performed at many stages in the
development of a new pharmaceutical or intervention. An example of the pre-
marketing use of pharmacoeconomics to assess the impact is given in chapter
9. In this chapter, cost-eÍfectiveness analysis is used to project the vaccine
parameters, economic consequences and market size associated with HIV-1
vaccination of infants in sub-Saharan Africa through the Expanded Program
on Immunisation (EPI).
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This analysis is performed as a means of providing incentives for the researcl
for an effective HIV vaccine. It is concluded that if technological and financia
problems associated with the development and distribution of an HIV vaccinr
can be solved, HIV vaccination in Africa could be potentially cost-effectivr
from a healthcare provider's perspective. Since the vaccine needs to br
accessible to low-income countries, vaccine prices should be low. Given thr
costs of R&D needed to develop such a vaccine (mean cost per NCE: >$80i
million), these results illustrate the need for additional funding of R&D. Thir
would be necessary to provide the necessary incentives for research.
In part 3 of this thesis, some aspects of HIV prevention are evaluated. Ir
chapter L0, the cost-effectiveness of universal HIV screening of attenders o.
clinics for sexually transmitted diseases is discussed. A Bernoulli model for tht
secondary transmission of HIV is presented that links epidemiological data or
infection with HIV and other STD in patients attending a STD-clinic ir
Amsterdam from L991 to 1997. The number of secondary HIV infectionr
caused by attenders of the STD-clinic can be calculated using this model
Combined with data on the health and monetary benefits of averting HIV
infection and costs of HlV-screening, the cost-effectiveness of HlV-screening o
attenders of the STD-clinic was assessed. An increased risk for HIV infectior
was found in STD clinic attenders infected with another STD (Odds raf.o:2.07',
The risk differed for specific STDs, highest odds ratios were found for syphili
and gonorrhoea. Screening of all attenders was estimated at net costs o
€82,550 per secondary infection averted. The cost-effectiveness ratio range
between €680 and €9340 per life year gained, depending on the value of ke
parameters used in the model.
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Amsterdam has a relatively high prevalence of HIV and results obtained in
chapter L0 therefore may not be transferable to lower HIV prevalence settings,
such as the rest of The Netherlands. In chapter L1-, the cost-effectiveness of this
intervention was investigated for lower prevalence settings. Data was used
from the STD-clinic in Rotterdam, the Netherlands, a city with a relatively low
HIV prevalence. Our results for the Netherlands may indicate the effects of
HIV screening of attenders of STD-clinics in other regions of countries with a
low-level HIV epidemic. For this analysis, we linked a Bernoulli model,
estimating the probability of secondary infection by an asymptomatic HIV-
infected patient, to epidemiological data on the prevalence of HIV in a STD-
clinic in Rotterdam from L995 to 1998. With screening of all attenders of the
EMCR STD-clinic, 8.4 cases of HlV-infection are prevented, at a cost of €98,860
per secondary infection averted. The results display a favourable economic
profile. Routine HIV screening in STD-clinics should be considered as a highly
cost-effective prevention measure even in countries with a low HIV
prevalence.
In chapter L2 of this thesis, the pharmacoeconomic profile of highly active
antiretroviral therapies (HAART) in HIV/AIDS is evaluated. An overview of
the studies that have been published is presented as well as the most
important outcomes and methodological issues. The articles studied in this
review provide a clear indication about the pharmacoeconomic effects of the
difÍerent antiretroviral therapies on health economics and patient outcomes.
The use of HAART (highly active antiretroviral therapy) is associated with a
large increase in costs for pharmaceuticals, which are in many studies offset by
a large decline in opportunistic infections and related hospitalisations. From a
pharmacoeconomic viewpoint, HAART is preferable above dual NRTI and
single NRTI use.
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Chapter L3 lists the main findings of this thesis, ranging from methodological
issues such as the choice of the cost-effectiveness model or the valuing of
future health benefits, to practical applications. The increasing importance of
pharmacoeconomic evaluations for policy-making is noted and some
limitations are discussed. The importance of other factors, such as ethical and
political, is stressed as drivers for the decision-making process.
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